Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Clin Cancer Res. 2020 Nov 30;27(4):983–991. doi: 10.1158/1078-0432.CCR-20-3089

Figure 1. Clinical efficacy of adavosertib with cisplatin in metastatic TNBC.

Figure 1.

A) Waterfall plot of best tumor size change and overall response rate (ORR): two patients with > 30% reduction in tumor size had new lesions on initial scan or on a subsequent scan after initial scans showed stable disease and then unconfirmed partial response. In addition, two of the three complete responders had lymph nodes as target lesions, which are considered normal when the short axis measures < 10 mm and so do not require a 100% reduction in lesion size to be classified as a complete response.30 B, C) Kaplan-Meier curves for progression-free survival (PFS, B) and overall survival (OS, C).